Advertisement
Advertisement
U.S. Markets open in 58 mins
Advertisement
Advertisement
Advertisement
Advertisement

Summit Hotel Properties, Inc. (INN)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
8.83-0.13 (-1.45%)
At close: 04:00PM EDT
9.07 +0.24 (+2.72%)
After hours: 04:08PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close8.93
Open8.90
Bid0.00 x 800
Ask0.00 x 1200
Day's Range8.90 - 9.09
52 Week Range6.70 - 10.94
Volume489,826
Avg. Volume765,751
Market Cap939.962M
Beta (5Y Monthly)2.04
PE Ratio (TTM)N/A
EPS (TTM)-1.11
Earnings DateFeb 21, 2022 - Feb 25, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateFeb 13, 2020
1y Target Est11.83
  • Newsfile

    Innocan Pharma Meets Pre-Clinical End-Point in Pilot Pain Study on Dogs Using LPT Liposome Technology

    6 dogs suffering from osteoarthritis and lameness demonstrated CBD concentrations 6 weeks after a single injectionPain and well-being scores improved following treatmentHerzliya, Israel and Calgary, Alberta--(Newsfile Corp. - August 17, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce positive partial results in a pilot pain study in dogs using the LPT CBD Liposomal Delivery Platform.Six dogs suffering from osteoarthriti

  • Newsfile

    Innocan Pharma Is Reaching Close to 100% CBD Bioavailability In a Dog Clinical Study For its Proprietary LPT CBD Liposomal Delivery Platform

    First results from a study on dogs showed close to 100% bioavailability of CBD using Innocan's LPT technologyThis is compared to 6.5-20% bioavailability in humans when administered orallyHerzliya, Israel and Calgary, Alberta--(Newsfile Corp. - August 11, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce results that approached 100% bioavailability following subcutaneous injection of its CBD proprietary LPT delivery system

  • Newsfile

    Innocan Pharma Files PCT Patent Application for Novel Composition for Preventing and Treating Hair Loss

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - August 5, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce that it has filed a new patent application (PCT) entitled "compositions for treatment of hair loss", claiming priority from an earlier US provisional patent application. The composition developed by Innocan research and development and disclosed in the current PCT can be used to treat and prevent ...

Advertisement
Advertisement